# NCT04526899 (NCT04526899)

> A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04526899
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: BioNTech SE
- Conditions: Melanoma Stage III; Melanoma Stage IV; Unresectable Melanoma
- Interventions: BNT111; Cemiplimab
- Enrollment: 184
- Primary outcome: Arm 1: Objective Response Rate (ORR)

## Indexed commentary on NCT04526899 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04526899